Oncocyte (NASDAQ:IMDX) Releases Quarterly Earnings Results

Oncocyte (NASDAQ:IMDX) announced its quarterly earnings results on Monday. The company reported ($0.23) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $0.24 million during the quarter.

Here are the key takeaways from Oncocyte’s conference call:

• FDA marketing authorization remains targeted for later this year for GraftAssureDx. The company said the FDA’s information requests appeared routine and addressable, with an SIR meeting planned to align on the response before resubmission, though timing remains outside its control.
• Medicare’s expanded MolDX coverage, increasing potential kidney-transplant surveillance testing from eight to 14 tests in the first three years, could improve the economic case for in-house testing. Management believes this could expand its stated $2 billion TAM as testing frequency, therapy monitoring, and additional organ indications grow.
• Head-to-head data showed clinical equivalence to leading centralized laboratory assays, driving interest from major U.S. transplant centers and reference labs. More than half of the top 10 U.S. transplant centers are engaged through the FDA program or registry, and management believes it has roughly a two-year lead in kitted product development.
• Second-quarter cash burn was $10 million, and the company now expects approximately $8 million of quarterly cash burn in the second half of the year, above its prior $6 million estimate. Higher spending reflects regulatory completion costs, registry activities, and preparations for commercial launch, although management said it is evaluating ways to extend its runway.
• European regulatory progress appears favorable, with IVDR submission still targeted for the second half of the year and U.K. self-certification expected to be easier. However, broader European adoption remains dependent on reimbursement expansion and clinical catalysts such as routine approval of anti-CD38 therapies.

Oncocyte Price Performance

NASDAQ IMDX traded down $0.17 during trading on Wednesday, hitting $4.25. The company’s stock had a trading volume of 54,430 shares, compared to its average volume of 228,829. The company has a market cap of $137.39 million, a PE ratio of -2.85 and a beta of 1.79. The business’s 50 day simple moving average is $5.18 and its 200-day simple moving average is $5.12. Oncocyte has a fifty-two week low of $2.33 and a fifty-two week high of $8.51.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Wall Street Zen raised Oncocyte from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Oncocyte in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Oncocyte presently has an average rating of “Hold” and an average target price of $12.00.

About Oncocyte

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.